Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV
In our study, no significant effect of pregnancy on rilpivirine pharmacokinetic parameters was reported. No dose adjustment for orally-administered rilpivirine should be recommended in this setting.
Authors
- Benjamin Kably (ORCID: https://orcid.org/0000-0002-9730-4814)
- N Hamani
- Quentin Le Hingrat (ORCID: https://orcid.org/0000-0001-9017-4941)
- Laurent Mandelbrot (ORCID: https://orcid.org/0000-0002-5883-7597)
- Marc Wirden (ORCID: https://orcid.org/0009-0003-3723-4142)
- Gilles Peytavin (ORCID: https://orcid.org/0000-0002-4359-537X)
- Minh Lê (ORCID: https://orcid.org/0000-0002-4670-8288)
- Roland Tubiana
- Zélie Julia
- Jade Ghosn (ORCID: https://orcid.org/0000-0003-0274-5199)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Hôpital Louis-Mourier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1016/j.ijid.2025.108145
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00